Skip to main
DBVT

DBVT Stock Forecast & Price Target

DBVT Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DBV Technologies is well-positioned to spearhead the immunotherapy space for pediatric peanut allergy with its novel Viaskin technology platform. Key potential catalysts driving stock performance include the upcoming BLA submissions for children (1H26) and toddlers (2H26), as well as the completion of the COMFORT-TODDLER 6-month supplemental safety study. The company's proforma cash position of ~$284MM is expected to provide sufficient runway into 2Q27 to support operations until commercialization. However, there are some risks to consider, including clinical and regulatory risk, financial risk as the company continues to incur losses, and commercial risks associated with market potential and patient perception of treatment effectiveness. Our analysis, based on a sum-of-the-parts (SOTP) net-present-value (NPV) valuation, sets our PT at $51, considering the probability-adjusted NPV of VIASKIN peanut patch in pediatric peanut allergies, pipeline value, and the company's anticipated YE26 cash position.

Bears say

DBV Technologies is facing delays and setbacks in its Viaskin Peanut treatment for peanut allergies, including issues found in the COMFORT-TODDLER study and the need for additional safety studies requested by the FDA for different age groups. These delays and potential competition in the immunotherapy space could impact the company's future revenue potential. Additionally, the company has reported a significant net loss in the first quarter of 2026 and has a limited cash position, which could potentially lead to a need for additional funding in the future.

DBVT has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast

Analysts have given DBVT a Buy based on their latest research and market trends.

According to 4 analysts, DBVT has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DBV Technologies SA Sponsored ADR (DBVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.